Cord blood bank

Be The Match BioTherapies® Marks Cord Blood Awareness Month with the Announcement of the Cord Blood Bank Alliance

Retrieved on: 
Monday, July 10, 2023
Health, National Marrow Donor Program, Stem Cell Therapeutic and Research Act of 2005, Cord, The Cord of Life, Research, Cord blood, Government, MD, Patient, Bloodworks Northwest, NMDP, Blood, Cord blood bank, Stem cell, CBUS, Environment, Pharmaceutical industry, Medical device, Match

MINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- In anticipation of Cord Blood Awareness Month this July, Be The Match BioTherapies ® , an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced the formation of the Be The Match BioTherapies Cord Blood Bank Alliance (CBBA).

Key Points: 
  • MINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- In anticipation of Cord Blood Awareness Month this July, Be The Match BioTherapies ® , an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced the formation of the Be The Match BioTherapies Cord Blood Bank Alliance (CBBA).
  • Members include Bloodworks Northwest, the Cleveland Cord Blood Center, Cord for Life, the Carolinas Cord Blood Bank, Vitalant, South Texas Blood & Tissue, Versiti, and StemCyte.
  • In this role, the organization works with public cord blood banks, doctors and researchers to continually improve cord blood transplantation and educate medical professionals and the public.
  • This work expanded the organization’s deep relationships with cord blood banks and positioned it to take a leadership role in creating the CBBA.

Be The Match BioTherapies® Now Offers A Central Point of Access To Fully-Characterized Cord Blood Units for Commercial and Clinical Use

Retrieved on: 
Tuesday, August 9, 2022
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, FDA, Cord blood bank, Research, History, Patient, Center, Partnership, Center for International Blood and Marrow Transplant Research, Safety, RUO, CBU, Onboarding, Solution, Collection, Time, National Marrow Donor Program, CBUS, Association, Temperature, Pharmaceutical industry, Match

Be The Match BioTherapies announced it is now providing cryopreserved Cord Blood Units as allogeneic cell therapy starting material for non-clinical, clinical, and commercial use.

Key Points: 
  • Be The Match BioTherapies announced it is now providing cryopreserved Cord Blood Units as allogeneic cell therapy starting material for non-clinical, clinical, and commercial use.
  • The Be The Match Registry, with more than 266,000 fully-characterized cord blood units (CBU) from domestic cord blood banks, provides extensive characterization information about each CBU to allow for therapy-matched unit identification.
  • Once located, developers must qualify and contract with each cord blood bank, which takes time and resources.
  • Through a single point of access, Be The Match BioTherapies centralizes access to fully characterized CBUs through a Cord Blood Bank Alliance, effectively eliminating these challenges.

Cleveland Cord Blood Center and Deverra Therapeutics Announce Agreement

Retrieved on: 
Tuesday, April 5, 2022
Therapy, Leukemia, Organization, CCBC, Partnership, EVP, Transplant, AML, Multimedia, Cord blood bank, Adult, Lymphoma, CSO, Incidence, Cancer, CEO, Lists of diseases, Center, W-inds, COVID-19, Randomized controlled trial, Development, NK, FDA, Patient, Collection, Pharmaceutical industry, Notch, Research, Deverra

CLEVELAND and SEATTLE, April 5, 2022 /PRNewswire/ -- Deverra Therapeutics, Inc., a leading clinical-stage company in Seattle, Washington, developing therapeutic allogeneic off-the-shelf cord blood-derived cell products, has entered into a manufacturing service agreement with the Cleveland Cell Therapy Incubator (CCTI), a subsidiary of the Cleveland Cord Blood Center (CCBC).

Key Points: 
  • CLEVELAND and SEATTLE, April 5, 2022 /PRNewswire/ -- Deverra Therapeutics, Inc. , a leading clinical-stage company in Seattle, Washington, developing therapeutic allogeneic off-the-shelf cord blood-derived cell products, has entered into a manufacturing service agreement with the Cleveland Cell Therapy Incubator (CCTI), a subsidiary of the Cleveland Cord Blood Center (CCBC).
  • With the agreement, the collaborations will extend to using these supplies for manufacture of Deverra products at CCTI's Cleveland, Ohio facility, providing Deverra with the flexibility for product sourcing to expand manufacturing.
  • The Cleveland Cord Blood Center (CCBC), is a not-for-profit 501(c)(3), independent public cord blood bank serving as a leader in the collection, processing, storage and distribution of quality cord blood stem cell units for transplantation in patients with life threatening disorders such as leukemia, lymphoma and immune system disorders.
  • Launched in 2008, The Cleveland Cord Blood Center was founded in 2008 by Mary J. Laughlin, M.D., who performed one of the world's first successful umbilical cord blood stem cell transplants on an adult leukemia patient in 1995.

Ready to Treat Over 80 Life-Threatening Diseases, Discover the Potential of Cord Blood during World Cord Blood Day 2021

Retrieved on: 
Tuesday, October 5, 2021
Blood, Social media, Temperature, COVID-19, Regenerative medicine, Cord blood bank, Umbilical cord, Leukemia, Parent, Accreditation, World Marrow Donor Association, Bone marrow, Stroke, Partner, Student, Bone marrow failure, Hospital, Nursing, Method, Lymphoma, Cerebral palsy, Education, FACT, Child, Placenta, Sickle cell disease, Research, Waste, Thalassemia, Foundation, Laboratory, NMDP, Autism, Birth control, Pharmaceutical industry

Cord blood is the blood left in the umbilical cord and placenta following the birth of a child.

Key Points: 
  • Cord blood is the blood left in the umbilical cord and placenta following the birth of a child.
  • During World Cord Blood Day 2021, participants will learn how cord blood is used to treat over 80 life-threatening diseases such as leukemia and lymphoma, bone marrow failure, immune deficiency diseases and inherited blood disorders such as thalassemia and sickle cell disease.
  • Organized by Save the Cord Foundation, a 501c3 non-profit, World Cord Blood Day 2021 is officially sponsored by QuickSTAT Global Life Science Logistics, recognized leader in medical shipping and healthcare logistics.
  • "QuickSTAT, part of Kuehne+Nagel, is proud to sponsor the 5th annual World Cord Blood Day to help support and educate the healthcare community and expectant parents about the life-saving value of cord blood stem cells.

Singapore cord blood bank Cryoviva establishes footprint in the UAE

Retrieved on: 
Tuesday, July 27, 2021
Blood, Stem cells, Branches of biology, Countries, Western Asia, Cord blood bank, Sibling, Cord blood, United Arab Emirates, Dubai, Cordlife

Many families in the UAE have opted to store their baby's cord blood in Cryoviva's facility in Singapore.

Key Points: 
  • Many families in the UAE have opted to store their baby's cord blood in Cryoviva's facility in Singapore.
  • Singapore, July 27, 2021 - (ACN Newswire) - Family cord blood bank Cryoviva Singapore is pleased to announce that it has made a successful foray into the UAE market in line with its strategic growth plans.
  • After 7 years of serving young families in Singapore, the expansion into Dubai and the other Emirates in the UAE is an important milestone for Cryoviva.
  • Established in 2014, Cryoviva (https://cryoviva.com.sg) is a well-regarded family cord blood bank in Singapore.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2021 Financial Results

Retrieved on: 
Friday, July 16, 2021
Branches of biology, Biology, Stem cells, Life sciences, Blood, Cryo-Cell International, Childbirth, Cord blood bank, Cloning, Cord blood, Draft:Americord Registry, Cryo-Save

OLDSMAR, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2021.

Key Points: 
  • OLDSMAR, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2021.
  • Consolidated revenues for the second quarter of fiscal 2021 were $7.21 million compared to $7.87 million for the second quarter of fiscal 2020, an 8% decrease.
  • The revenues for the second quarter of fiscal 2021 consisted of $7.16 million in processing and storage fee revenue and $46,000 in public banking revenue compared to $7.40 million in processing and storage fee revenue, $57,000 in product revenue, $214,000 in public banking revenue and $202,000 in license and royalty income for the second quarter of fiscal 2020.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.

Americord Promotes Client Bill of Rights During Cord Blood Awareness Month

Retrieved on: 
Thursday, July 1, 2021
General Health, Hospitals, Consumer, Health, Baby, Maternity, Branches of biology, Stem cells, Biology, Anatomy, Blood, Childbirth, Cord blood, Placenta, Cord blood bank, Umbilical cord

As part of Cord Blood Awareness Month, Americord Registry reminds expecting parents of the Americord Client Bill of Rights.

Key Points: 
  • As part of Cord Blood Awareness Month, Americord Registry reminds expecting parents of the Americord Client Bill of Rights.
  • The Client Bill of Rights informs and clarifies the outcomes and benefits from banking a childs cord blood, cord tissue, and placental tissue.
  • We believe Cord Blood Awareness Month is a fitting time to remind expecting parents of our Client Bill of Rights, said Martin Smithmyer, Founder and CEO.
  • Cord Blood Awareness Month is an important reminder for families to research their options.

Gulf Coast Regional Blood Center first in US to implement e-Delphyn ©.

Retrieved on: 
Friday, June 25, 2021
Medical specialties, Blood, Branches of biology, Transfusion medicine, Blood donation, Stem cells, Hematology, Gulf Coast Regional Blood Center, Cord blood bank, Middleware, Cord blood, Blood bank

HOUSTON, June 25, 2021 /PRNewswire/ -- Gulf Coast Regional Blood Center whose mission is to partner with the community to help save and sustain lives via blood services did successfully go-live with e-Delphyn, GPI's next generation of web-based Blood Establishment Computer Software.

Key Points: 
  • HOUSTON, June 25, 2021 /PRNewswire/ -- Gulf Coast Regional Blood Center whose mission is to partner with the community to help save and sustain lives via blood services did successfully go-live with e-Delphyn, GPI's next generation of web-based Blood Establishment Computer Software.
  • GPI delivers specialized services &cloud-based software solutionsforBlood Donor Centers, Hospital Blood Banks, Cell Therapy Labs, Cord Blood Banks, LIS/Middleware, andHuman Milk Banks in more than 60 countries.
  • After having been deployed in more than 60 countries in the last decade and after having completed all regulatory steps to be ready for the US market, e-Delphyn went live on June 1st, 2021, at Gulf Coast Regional Blood Center.
  • As Gulf Coast Regional Blood Center continues to grow its client testing services, e-Delphyn includes a LIS (Laboratory Information System) designed to integrate all client testing features.

Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Stem cells, Biology, Life sciences, Cord blood bank, Cord blood, Umbilical cord, Hematopoietic stem cell, Cordlife, LifeCell International

HONG KONG, June 22, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the fourth quarterand full year fiscal 2021 on Monday, June 28, 2021, after the U.S. market close.

Key Points: 
  • HONG KONG, June 22, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services,today announced that it plans to release unaudited financial results for the fourth quarterand full year fiscal 2021 on Monday, June 28, 2021, after the U.S. market close.
  • ET on Tuesday, June 29, 2021 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session.
  • Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.
  • Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.

StemCyte Inc. Extends Umbilical Cord Blood Collection Operation at Three Hospital Collection Sites in Southern California

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Stem cells, Biology, Blood, Childbirth, Embryology, Cord blood bank, Sibling, Cord blood, Umbilical cord, Umbilical, Relicord

As these sites employ a hybrid collector-physician model, physicians and midwives will continue to collect cord blood afterhours.

Key Points: 
  • As these sites employ a hybrid collector-physician model, physicians and midwives will continue to collect cord blood afterhours.
  • This added coverage to each site allows StemCyte to be able to offer more patients the opportunity to participate in California\'s Umbilical Cord Blood Collection Program.\nThis Umbilical Cord Blood Collection Program (UCBCP) is aCalifornia statewide program administered by UC Davis Health.
  • "It is a great honor and privilege for StemCyte to be partnered with UC Davis for California\'s Umbilical Cord Blood Program (UCBCP).
  • The collection service is the state\'s first comprehensive public system for collecting cord blood that will be stored at an established, qualified cord blood bank like StemCyte.